Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease, Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/25/2019 |
| Start Date: | July 24, 2017 |
| End Date: | October 30, 2018 |
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections
The purpose of this study is to assess the effect of a new critical pathway (use of
guideline-based patient identification criteria and for those who meet these criteria, use of
dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin
Structure Infections)
guideline-based patient identification criteria and for those who meet these criteria, use of
dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin
Structure Infections)
Inclusion Criteria:
- Admitted patients who meets the clinical definition for Acute Bacterial Skin and Skin
Structure Infections (ABSSSI)
- Known or suspected gram-positive infection.
Exclusion Criteria:
- Known or suspected gram-negative infections, anaerobic infections, or fungemia
- Known or suspected infections that are severe, life threatening or are not included in
the ABSSSI Food and Drug Administration (FDA) guidance
- Injection drug users with a fever
- Severe neurological disorder leading to immobility or confined to a wheelchair
- Bilateral Lower extremity involvement of the suspected infection.
We found this trial at
1
site
Click here to add this to my saved trials
